Study S000741

Prediction of Response to GLP-1/GIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07653412
Acronym: Diagenix
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 220
Start: 2026-04-22
Primary completion: 2027-01-30
Lead sponsor: National and Kapodistrian University of Athens
Conditions: Obesity (Disorder); Anti-obesity Agents; Precision Medicine
Interventions: DRUG:Semaglutide or Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage weight loss at 6 months [6 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010987	Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, The New England journal of medicine	2022	Randomized trial	PMID 35658024 DOI	registry reference RESULT:35658024
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference RESULT:33567185